Public market insider buying at Satellos Bioscience (MSCL)

Public market insider buying at Satellos Bioscience (T:MSCL)

Brian Matthew Bloom, a Director and 10% Holder, acquired 72,000 Common Shares on an indirect ownership basis for registered holder 2194655 Ontario Inc. at a price of $1.436 on September 23rd, 2021. This represents a $103,392 investment into the company's shares and an account share holdings change of 1.2%.

Satellos Bioscience is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

iCo Therapeutics Inc. (iCo) is a Canada-based biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat sight-and life-threatening diseases. The Company principally focuses on in-licensing drug candidates with a clinical history, and re-dose, reformulate and develop drug candidates for the treatment of sight-and life-threatening diseases. The Company's product candidates include iCo-007, iCo-008 and an Oral AmpB Delivery System. The Company has initiated Phase II clinical trial for iCo-007. iCo-008 is a human monoclonal antibody that is offered to treat sight threatening forms of allergic conjunctivitis by neutralizing eotaxin-1, a ligand to the chemokine receptor CCR3. Oral AmpB Delivery System is a toxic option for the treatment of serious systemic fungal infections. The Company has completed pre-clinical studies for iCo's Oral AmpB Delivery System.